Organogenesis (NASDAQ:ORGO) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Organogenesis (NASDAQ:ORGOFree Report) in a research note published on Wednesday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $5.00 price target on the stock.

ORGO has been the topic of a number of other research reports. BTIG Research raised their price target on shares of Organogenesis from $4.00 to $6.00 and gave the company a buy rating in a report on Wednesday, December 27th. Morgan Stanley raised their price target on shares of Organogenesis from $3.00 to $3.50 and gave the company an equal weight rating in a report on Tuesday, November 14th.

Check Out Our Latest Stock Report on ORGO

Organogenesis Stock Performance

Shares of ORGO stock opened at $3.56 on Wednesday. Organogenesis has a one year low of $1.79 and a one year high of $4.70. The company’s 50-day moving average is $3.63 and its 200 day moving average is $3.07. The company has a market capitalization of $470.06 million, a price-to-earnings ratio of 35.60 and a beta of 1.59. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.43 and a current ratio of 2.77.

Organogenesis (NASDAQ:ORGOGet Free Report) last announced its quarterly earnings results on Thursday, November 9th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.01. The firm had revenue of $108.53 million for the quarter, compared to the consensus estimate of $112.75 million. Organogenesis had a net margin of 2.90% and a return on equity of 4.83%. Sell-side analysts expect that Organogenesis will post 0.04 EPS for the current fiscal year.

Insiders Place Their Bets

In other Organogenesis news, major shareholder Albert Erani sold 197,921 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $4.37, for a total transaction of $864,914.77. Following the sale, the insider now owns 59,025,106 shares in the company, valued at approximately $257,939,713.22. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 34.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Morgan Stanley boosted its stake in Organogenesis by 633.5% during the third quarter. Morgan Stanley now owns 6,940,544 shares of the company’s stock worth $22,071,000 after buying an additional 5,994,373 shares during the period. State Street Corp boosted its stake in Organogenesis by 39.6% during the second quarter. State Street Corp now owns 6,170,589 shares of the company’s stock worth $30,112,000 after buying an additional 1,750,534 shares during the period. BlackRock Inc. boosted its stake in Organogenesis by 17.1% during the first quarter. BlackRock Inc. now owns 9,652,188 shares of the company’s stock worth $73,551,000 after buying an additional 1,412,356 shares during the period. Polar Asset Management Partners Inc. purchased a new position in Organogenesis during the second quarter worth $4,119,000. Finally, Federated Hermes Inc. boosted its stake in Organogenesis by 1,086.6% during the first quarter. Federated Hermes Inc. now owns 1,030,743 shares of the company’s stock worth $7,854,000 after buying an additional 943,875 shares during the period. 39.48% of the stock is owned by hedge funds and other institutional investors.

About Organogenesis

(Get Free Report)

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage.

Featured Articles

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.